Skip to content
Screener

Harmony Biosciences Holdings, Inc. HRMY G&A

G&A at other companies

Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$27.49M+110%
AdaptHealth logo
AdaptHealthAHCO
$95.91M+10.4%
RFL
Rafael Holdings, Inc.RFL
$2.14M-32.5%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$10.45M+13.9%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$2.26B+13.1%
Enterprise value$1.83B+12.9%
P/E15.5×+4.5×
P/S2.5×-0.1×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:16 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056720
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Operating expenses:
Research and development69,38334,540
Sales and marketing31,69430,711
General and administrative32,50731,243
Total operating expenses133,58496,494
Operating income37,29156,245
Other expense, net(127)(276)
Interest expense(3,234)(3,836)

Item 1. Financial Statements

FAQ

What is Harmony Biosciences Holdings, Inc.'s G&A?
Harmony Biosciences Holdings, Inc. (HRMY) reported G&A of $32.51M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s G&A changed year-over-year?
Harmony Biosciences Holdings, Inc.'s G&A increased by 4.0% year-over-year, from $31.24M to $32.51M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s G&A?
Over 4 years (2021 to 2025), Harmony Biosciences Holdings, Inc.'s G&A has grown at a 24.3% compound annual growth rate (CAGR), from $63.91M to $152.54M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Harmony Biosciences Holdings, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude